Gilead Announces 48-Week Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For The Treatment Of Chronic Hepatitis B

Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 6th, 2007

Comments are closed.

« NAEA Opposed To Providing Contraception In Public Schools - More Than Half Of People Surveyed By AP Not Even Parents Statement From The Secretary Of State On The Health Protection Agency Figures, UK »

Fioricet Supply - Buy Online: Fioricet is used to treat tension headaches.
Yo Durgs - Buy Your Pills: Getting drugs online gives you many advantages like privacy, saving money and saving TIME
Your Health Rx - : Your Health Rx
Drug any time - : Drug any time
Online rx pharma - : Online rx pharma
Prescript Medicine - : Prescript Medicine
Latest News...